STOCK TITAN

NLS Pharmaceutics to Present at the Access to Giving Virtual Investor Conference on July 15th

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) announced that CEO Alex Zwyer will present a corporate overview at the First Annual Access to Giving Virtual Investor Conference from July 13-15, 2021. The presentation is scheduled for July 15th at 9:00 am ET, followed by a Q&A session. NLS focuses on innovative therapies for rare central nervous system disorders, with its lead candidate, Quilience®, aimed at treating narcolepsy, receiving Orphan Drug Designations in the U.S. and Europe.

Positive
  • None.
Negative
  • None.

STANS, SWITZERLAND / ACCESSWIRE / July 9, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present a corporate overview at the First Annual Access to Giving Virtual Investor Conference which will take place July 13-15, 2021.

Mr. Zwyer will deliver his corporate presentation on July 15th at 9:00am ET and investors can access the event here. A Question & Answer session will follow the presentation.

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating Nolazol® (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy.

Corporate Contact

Alex Zwyer, CEO: +41 41 618 80 00

Investor Relations Contact

Cindy Rizzo: +1 908-229-7050
www.nlspharma.com

SOURCE: NLS Pharmaceutics AG



View source version on accesswire.com:
https://www.accesswire.com/654818/NLS-Pharmaceutics-to-Present-at-the-Access-to-Giving-Virtual-Investor-Conference-on-July-15th

FAQ

When is NLS Pharmaceutics scheduled to present at the Access to Giving Virtual Investor Conference?

NLS Pharmaceutics will present on July 15, 2021, at 9:00 am ET.

What is the focus of NLS Pharmaceutics?

NLS Pharmaceutics focuses on developing therapies for rare and complex central nervous system disorders.

What is Quilience® and what is it used for?

Quilience® is NLS's lead product candidate, developed for the treatment of narcolepsy.

What designations has Quilience® received?

Quilience® has received Orphan Drug Designations in both the U.S. and Europe.

What was the outcome of NLS's phase 2 study for Nolazol®?

The phase 2 study for Nolazol® met all primary and secondary endpoints and was well-tolerated.

NLS Pharmaceutics Ltd. Ordinary Shares

NASDAQ:NLSP

NLSP Rankings

NLSP Latest News

NLSP Stock Data

4.49M
1.56M
40.85%
19.4%
2.36%
Biotechnology
Healthcare
Link
United States of America
Zurich